Adenocarcinoma — Trials

Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,751
Recruiting: 1,519
Ph III recruiting: 167
Growth YoY: +8.6%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,318)

clinicaltrialsPublishedShowing 401–402 of 402 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03308396	Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer	active not recruiting	Phase 1 / Phase 2	57	Ajjai Alva, MDOTHER	1	Feb 17, 2022	clinicaltrials
NCT02493582	The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR	active not recruiting	Phase 2	400	The First People's Hospital of ChangzhouOTHER	0	Feb 5, 2016	clinicaltrials